Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and RAD001 in Advanced Pancreatic Cancer
NCT00640978Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in pancreatic cancer (PC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Survival at 6 months. Started Mar 2008; status: terminated.
02
Drugs
everolimus
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00640978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640978.